Eric Vibert

Eric Vibert

Auto-generated profile, based on publicly available information

Eric Vibert

Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, Paris, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of Hepatology
Verified
Journal Article
Open access
EVEric Vibert
Eric Vibert
MSMyron Schwartz
Myron Schwartz
KOKim M. Olthoff
Kim M. Olthoff
It would be impossible to summarise all of the significant developments in the surgical management of hepatocellular carcinoma (HCC), even just over the past year, in a manuscript of this scope. Thus, we have selected topics for discussion that are the subject of current controversy and have attempted to present balanced points of view. Hepatic resection and transplantation are both mature modalities, and for the most part technical advances and improvements in candidate selection are incremental. The ability to readily cure hepatitis C stands out as the most impactful development in the field over recent years, especially in Western countries where hepatitis C has long been the chief aetiology underlying HCC and a predictor of poor outcomes after surgery, but its full implications remain to be clarified. The rising incidence of non-alcoholic steatohepatitis-related HCC and what it means with regard to surgical HCC management is an area of great current interest. With advancing technology, non-surgical locoregional treatments are gaining increasing application as potentially curative therapies. In addition, the advances in molecular and genomic assessment of HCC hold promise for personalising treatment and prognostication. The possible role of immunotherapy as an adjuvant to resection is being aggressively investigated. While liver surgery maintains an important role, the care of patients with HCC is more and more a team effort and needs to take place in the context of a well-integrated interdisciplinary programme to achieve the best outcomes for patients.

7 November 2016 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
NGNicolas Golse
Nicolas Golse
PBPetru Octav Bucur
Petru Octav Bucur
OCOriana Ciacio
Oriana Ciacio
GPGabriella Pittau
Gabriella Pittau
ACAntonio Sa Cunha
Antonio Sa Cunha
EVEric Vibert
Eric Vibert
Although sarcopenia is a common complication of cirrhosis, its diagnosis remains nonconsensual: computed tomography (CT) scan determinations vary and no cutoff values have been established in cirrhotic populations undergoing liver transplantation (LT). Our aim was to compare the accuracy of the most widely used measurement techniques and to establish useful cutoffs in the setting of LT. From the 440 patients transplanted between January 2008 and May 2011 in our tertiary center, we selected 256 patients with cirrhosis for whom a recent CT scan was available during the 4 months prior to LT. We measured different muscle indexes: psoas muscle area (PMA), PMA normalized by height or body surface area (BSA), and the third lumbar vertebra skeletal muscle index (L3SMI). Receiver operating characteristic curves were evaluated and prognostic factors for post‐LT 1‐year survival were then analyzed. PMA offered better accuracy (area under the curve [AUC] = 0.753) than L3SMI (AUC = 0.707) and PMA/BSA (AUC = 0.732), and the same accuracy as PMA/squared height. So, for its accuracy and simplicity of use, the PMA index was used for the remainder of the analysis and to define sarcopenia. In men, the better cutoff value for PMA was 1561 mm2 (Se = 94%, Sp = 57%), whereas in women, it was 1464 mm2 (Se = 52%, Sp = 91%). A PMA lower than these values defined sarcopenia in patients with cirrhosis awaiting LT. One‐ and 5‐year overall survival rates were significantly poorer in the sarcopenic group (n = 57) than in the nonsarcopenic group (n = 199), at 59% versus 94% and 54% versus 80%, respectively (P < 0.001). In conclusion, pre‐LT PMA is a simple tool to assess sarcopenia. We established sex‐specific cutoff values (1561 mm2 in men, 1464 mm2 in women) in a cirrhotic population and showed that 1‐year survival was significantly poorer in sarcopenic patients. Liver Transplantation 23 143–154 2017 AASLD

24 February 2020 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
EMEleonora De Martin
Eleonora De Martin
MRMichael Rayar
Michael Rayar
NGNicolas Golse
Nicolas Golse
MDMargot Dupeux
Margot Dupeux
MGMaximiliano Gelli
Maximiliano Gelli
EVEric Vibert
Eric Vibert

1 November 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
MPMathieu Prodeau
Mathieu Prodeau
EDElodie Drumez
Elodie Drumez
ADAlain Duhamel
Alain Duhamel
EVEric Vibert
Eric Vibert
OFOlivier Farges
Olivier Farges
EBEmmanuel Boleslawski
Emmanuel Boleslawski

1 June 2018 in Surgery
Verified
Journal Article
Closed access
FAFernando A. Alvarez
Fernando A. Alvarez
DCDenis Castaing
Denis Castaing
RFRodrigo Figueroa
Rodrigo Figueroa
MAMarc Antoine Allard
Marc Antoine Allard
NGNicolas Golse
Nicolas Golse
EVEric Vibert
Eric Vibert

1 July 2019 in Annals of Surgery
Verified
Journal Article
Closed access
NGNicolas Golse
Nicolas Golse
NGNicola Guglielmo
Nicola Guglielmo
AMAlbert El Metni
Albert El Metni
FFFabio Frosio
Fabio Frosio
CCCyril Cosse
Cyril Cosse
EVEric Vibert
Eric Vibert
Background: Although many prognostic factors of primary graft dysfunction after liver transplantation (LT) are available, it remains difficult to predict failure in a given recipient. Objective: We aimed to determine whether the intraoperative assay of arterial lactate concentration at the end of LT (LCEOT) might constitute a reliable biological test to predict early outcomes [primary nonfunction (PNF), early graft dysfunction (EAD)]. Methods: We reviewed data from a prospective database in a single center concerning patients transplanted between January 2015 and December 2016 (n = 296). Results: There was no statistical imbalance between the training (year 2015) and validation groups (year 2016) for epidemiological and perioperative feature. Ten patients (3.4%) presented with PNF, and EAD occurred in 62 patients (20.9%); 9 patients died before postoperative day (POD) 90. LCEOT ≥5 mmol/L was the best cut-off point to predict PNF (Se=83.3%, SP=74.3%, positive likelihood ratio (LR+)=3.65, negative likelihood ratio (LR−)=0.25, diagnostic odds ratio (DOR)=14.44) and was predictive of PNF (P = 0.02), EAD (P = 0.05), and death ≤ POD90 (P = 0.06). Added to the validated BAR-score, LCEOT improved its predictive value regarding POD 90 survival with a better AUC (0.87) than BAR score (0.74). The predictive value of LCEOT was confirmed in the validation cohort. Conclusion: As a reflection of both hypoperfusion and tissue damage, the assay of arterial LCEOT ≥5 mmol/L appears to be a strong predictor of early graft outcomes and may be used as an endpoint in studies assessing the impact of perioperative management. Its accessibility and low cost could impose it as a reliable parameter to anticipate postoperative management and help clinicians for decision-making in the first PODs.